https://scholars.lib.ntu.edu.tw/handle/123456789/562488
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | JANN-YUAN WANG | en_US |
dc.contributor.author | PO-REN HSUEH | en_US |
dc.contributor.author | I-SHIOW JAN | en_US |
dc.contributor.author | LI-NA LEE | en_US |
dc.contributor.author | Liaw Y.-S. | en_US |
dc.contributor.author | PAN-CHYR YANG | en_US |
dc.contributor.author | KWEN-TAY LUH | en_US |
dc.date.accessioned | 2021-05-26T03:34:54Z | - |
dc.date.available | 2021-05-26T03:34:54Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0040-6376 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/562488 | - |
dc.description.abstract | Background: A study was conducted to evaluate the effect of the empirical use of fluoroquinolones on the timing of antituberculous treatment and the outcome of patients with tuberculosis in an endemic area. Methods: All patients with culture confirmed tuberculosis aged ?14 years diagnosed between July 2002 and December 2003 were included and their medical records were reviewed. Results: Seventy nine (14.4%) of the 548 tuberculosis patients identified received a fluoroquinolone (FQ group), 218 received a non-fluoroquinolone antibiotic (AB group), and 251 received no antibiotics before antituberculous treatment. Fifty two (65.8%) experienced clinical improvement after fluoroquinolone use. In the FQ group the median interval from the initial visit to starting antituberculous treatment was longer than in the AB group and in those who received no antibiotics (41 v 16 v 7 days), and the prognosis was worse (hazard ratio 6.88 (95% CI 1.84 to 25.72)). More patients in the FQ and AB groups were aged > 65 years (53.2% and 61.0% v 31.5%), had underlying disease (53.2% and 46.8% v 34.3%), and were hypoalbuminaemic (67.2% and 64.9% v 35.1%). Of the nine mycobacterial isolates obtained after fluoroquinolone use from nine patients whose initial isolates were susceptible to ofloxacin, one (11.1%) was resistant to ofloxacin (after fluoroquinolone use for 7 days). Independent factors for a poor prognosis included empirical fluoroquinolone use, age >65, underlying disease, hypoalbuminaemia, and lack of early antituberculous treatment. Conclusions: 14.4% of our patients with tuberculosis received a fluoroquinolone before the diagnosis. With a 34 day delay in antituberculous treatment and more frequent coexistence of underlying disease and hypoalbuminaemia, empirical fluoroquinolone treatment was associated with a poor outcome. Mycobacterium tuberculosis isolates could obtain ofloxacin resistance within 1 week. | - |
dc.relation.ispartof | Thorax | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | ciprofloxacin; levofloxacin; moxifloxacin; ofloxacin; quinolone derivative; tuberculostatic agent; adolescent; adult; aged; antibiotic resistance; article; child; controlled study; empirical research; female; human; hypoalbuminemia; infant; major clinical study; male; medical record; priority journal; prognosis; treatment outcome; tuberculosis; Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Endemic Diseases; Female; Fluoroquinolones; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Survival Analysis; Taiwan; Treatment Failure; Tuberculosis | - |
dc.title | Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1136/thx.2005.056887 | - |
dc.identifier.pmid | 16809417 | - |
dc.identifier.scopus | 2-s2.0-33750026219 | - |
dc.relation.pages | 903-908 | - |
dc.relation.journalvolume | 61 | - |
dc.relation.journalissue | 10 | - |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUHHC | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Biomedical Electronics and Bioinformatics | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.orcid | 0000-0003-3406-366X | - |
crisitem.author.orcid | 0000-0002-7502-9225 | - |
crisitem.author.orcid | 0000-0002-7936-5306 | - |
crisitem.author.orcid | 0000-0002-7654-2450 | - |
crisitem.author.orcid | 0000-0001-6330-6048 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | NTU Hsin-Chu Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Electrical Engineering and Computer Science | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。